Lisata Therapeutics, Inc. (LSTA)
NASDAQ: LSTA · IEX Real-Time Price · USD
3.550
0.00 (0.00%)
At close: Jul 19, 2024, 4:00 PM
3.560
+0.010 (0.28%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Company Description
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases.
Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.
Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Lisata Therapeutics, Inc.
| Country | United States |
| Founded | 1980 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. |
Contact Details
Address: 110 Allen Road, Second Floor Basking Ridge, New Jersey 07920 United States | |
| Phone | 908-229-2590 |
| Website | lisata.com |
Stock Details
| Ticker Symbol | LSTA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000320017 |
| CUSIP Number | 128058302 |
| ISIN Number | US1280583022 |
| Employer ID | 22-2343568 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. | President, Chief Executive Officer and Director |
| Dr. Kristen K. Buck M.D. | Executive Vice President of Research & Development and Chief Medical Officer |
| James Nisco | Vice President of Finance and Treasury |
| Tariq Imam | Vice President of Business Development and Operations and Corporate Counsel |
| Gregory S. Berkin | Chief Information Officer |
| John D. Menditto | Vice President of Investor Relations and Corporate Communications |
| Gail Holler | Vice President of Human Resources |
| Dr. William K. Sietsema Ph.D. | Vice President of Global Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 15, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 27, 2024 | 8-K | Current Report |
| May 9, 2024 | EFFECT | Notice of Effectiveness |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |
| May 6, 2024 | UPLOAD | Filing |
| May 1, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 17, 2024 | 8-K | Current Report |